Symbols

CGC

Canopy Growth·NASDAQ

--(--)

CGC fundamentals

CGC Q3 2026 Earnings

Canopy Growth (CGC) released its earnings on Feb 6, 2026: revenue was 54.41M (YoY +4.73%), beat estimates; EPS was -0.1314 (YoY +82.96%), missed estimates.

Revenue / YoY

54.41M

+4.73%

EPS / YoY

-0.1314

+82.96%

Report date

Feb 6, 2026

CGC Earnings Call Summary for Q3,2026

Record Financial Health: CAD 371M cash and net cash position of CAD 146M, with debt extended to 2031, enabling strategic flexibility.
MTL Acquisition: Expected to enhance Canadian medical leadership and fuel international growth, with accretive EBITDA contributions.
Canadian Growth Momentum: Medical cannabis revenue up 15% YoY, adult use up 8% YoY, driven by innovation and operational excellence.
Cost Efficiency: $29M annualized savings, narrowing Adjusted EBITDA loss to CAD 3M, with FY2027 positive EBITDA target.
European Expansion: Flower supply improvements and EU GMP certification position Canopy for European medical market growth.

Earnings

EPS

Revenue

Revenue & Expenses

CGC has released its 2026 Q3 earnings report, with revenue of 54.36M, reflecting a YoY change of 4.71%, and net profit of -45.67M, showing a YoY change of 46.04%. The Sankey diagram below clearly presents CGC's revenue sources and cost distribution.

Key Indicators

Canopy Growth (CGC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Canopy Growth (CGC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Canopy Growth (CGC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Canopy Growth (CGC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown